Phase 2 Results of Selinexor in Advanced De-Differentiated (DDLS) Liposarcoma (SEAL) Study: A Phase 2/3, Randomized, Double Blind, Placebo Controlled Crossover Study.
Mrinal M. Gounder,Neeta Somaiah,Steven Attia,Sant P. Chawla,Victor Manuel Villalobos,Bartosz Chmielowski,Melissa Amber Burgess,Gary K. Schwartz,Richard F. Riedel,Margaret von Mehren,Andrew J. Wagner,Edwin Choy,Shailendra Verma,Boyd Mudenda, Mara Sadanowicz,Jatin J. Shah,Lingling Li,Sharon Shacham,Michael G. Kauffman,Albiruni Ryan Abdul Razak Journal of clinical oncology（2018）
AI 理解论文
溯源树
样例
